PAC1-R null isoform expression in human prostate cancer tissue

Prostate

Volumn 66, Issue 5, 2006, Pages 514-521

  Mammi, Caterina ^a,c   Frajese, Giovanni V ^a   Vespasiani, Giuseppe ^a   Mariani, Stefania ^b   Gnessi, Lucio ^b   Farini, Donatella ^a   Fabbri, Andrea ^a   Frajese, Gaetano ^a   Moretti, Costanzo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

NE differentiation; PAC1 R; PACAP; Prostate cancer; SV1; SV2

Indexed keywords

GROWTH HORMONE RELEASING FACTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; ISOPROTEIN; MEMBRANE RECEPTOR; NEUROPEPTIDE; PAC1 RECEPTOR NULL; PAC1 SV1 PROTEIN; PAC1 SV2 PROTEIN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1; PRIMER DNA;

ACINAR CELL; ADULT; AGED; ARTICLE; CANCER TISSUE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATE SURGERY; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; PROTEIN VARIANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; BIOPSY; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENETICS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY; REFERENCE VALUE;

AGED; BASE SEQUENCE; BIOPSY; DNA PRIMERS; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE, TYPE I; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VARIATION (GENETICS);

EID: 33645342213     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20356     Document Type: Article

References (21)

1. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000;44(1):77-87.
2. Farini D, Puglianiello A, Mammi C, Siracusa G, Moretti C. Dual effect of pituitary adenylate cyclase activating polypeptide on prostate tumor LNCaP cells: Short- and long-term exposure affect proliferation and neuroendocrine differentiation. Endocrinology 2003;144(4):1631-1643.
3. Hosoya M, Kimura C, Ogi K, Ohkubo S, Miyamoto Y, Kugoh H, Shimizu M, Onda H, Oshimura M, Arimura A, et al. Structure of the human pituitary adenylate cyclase activating polypeptide (PACAP) gene. Biochem Biophys Acta 1992;1129(2):199-206.
4. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998;50(2):265-270.
5. Pisegna JR, Wank SA. Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. J Biol Chem 1996;271(29):17267-17274.
6. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: From structure to functions. Pharmacol Rev 2000;52(2):269-324.
7. McNeal JE, Cohen RJ, Brooks JD. Role of cytologic criteria in the histologic diagnosis of Gleason grade 1 prostatic adenocarcinoma. Hum Pathol 2001;32(4):441-446.
8. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162(1):156-159.
9. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351(15):1488-1490.
10. Garcia-Fernandez MO, Bodega G, Solano RM, Ruiz-Villaespesa A, Sanchez-Chapado M, Carmena MJ, Prieto JC. Expression and distribution of pituitary adenylate cyclase-activating peptide in human prostate and prostate cancer tissues. Regul Pept 2002;110(1):9-15.
11. Garcia-Fernandez MO, Solano RM, Carmena MJ, Busto R, Bodega G, Ruiz-Villaespesa A, Prieto JC, Sanchez-Chapado M. Expression of functional PACAP/VIP receptors in human prostate cancer and healthy tissue. Peptides 2003;24(6):893-902.
12. Solano RM., Carmena MJ., Carrero I., Cavallaro S., Roman F., Hueso C., et al. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide receptors in human benign hyperplastic prostate. Endocrinology 1996;137:2815-2822.
13. Solano RM., Carmena MJ. Busto R., Sanchez-Chapado M., Guijarro LG, Prieto JC. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate. Cell Signal 1999;11:813-819.
14. Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 2000;60(11):3105-3112.
15. Reubi JC. In vitro evaluation of VIP/PACAP receptors inhealthy and diseased human tissues. Clinical implications. Ann NY Acad Sci 2000;921:1-25.
16. Chen T, Cho RW, Stork PJ, Weber MJ. Elevation of cyclic adenosine 3′,5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. Cancer Res 1999;59(1):213-218.
17. Amorino GP, Parsons SJ. Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 2004;14(4):287-300.
18. Waschek JA, Richards ML, Bravo DT. Differential expression of VIP/PACAP receptor genes in breast, intestinal, and pancreatic cell lines. Cancer Lett 1995;92(2):143-149.
19. Shintani N, Suetake S, Hashimoto H, Koga K, Kasai A, Kawaguchi C, Morita Y, Hirose M, Sakai Y, Tomimoto S, Matsuda T, Baba A. Neuroprotective action of endogenous PACAP in cultured rat cortical neurons. Regul Pept 2005;126(1-2):123-128.
20. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350(22):2239-2246.
21. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351(2):125-135.